| Cat. No. |
Product Name |
Information |
| PC-28755 |
N6F11
GPX4 degrader, Ferroptosis inducer
|
N6F11 is a ferroptosis inducer and tumor-specificglutathione peroxidase 4 (GPX4) degrader, selectively induces ferroptosis by targeting TRIM25-mediated GPX4 degradation. |
| PC-28747 |
KY0418
GPX4 inhibitor
|
KY0418 is a specific covalent and orally bioavailable inhibitor of glutathione peroxidase 4 (GPX4) with inhibitory constant (Ki) of 0.3 uM, specifically targets GPX4SeCys46 to induce ferroptosis. |
| PC-28622 |
YL3147
Ferroptosis inhibitor
|
YL3147 is a radical-trapping antioxidant and potent ferroptosis inhibitor with EC50 of 0.8 nM (Erastin-induced ferroptosis in ES-2 cells), directly halting the propagation of lipid peroxidation and thereby blocking ferroptosis, protecting doxorubicin-induced cardiomyopathy in both acute and chronic murine models. |
| PC-28621 |
TZN-23
Ferroptosis inhibitor
|
TZN-23 is a potent and versatile ferroptosis inhibitor with EC50 of 13 nM across multiple cell lines, counteracts cell death induced by diverse ferroptosis inducers. |
| PC-28501 |
SB3507
Ferroptosis inhibitor
|
SB3507 is a potent, selective, broad-spectrum ferroptosis inhibitor with IC50 of 108 nM, suppresses lipid radical chain reactions without altering canonical protein expression or iron homeostasis. |
| PC-28364 |
THTZO4c
Ferroptosis inhibitor
|
THTZO4c is a potent nonclassical radical-trapping antioxidant and ferroptosis inhibitor with EC50 of 30 nM, effectively suppresses erastin-induced ferroptosis in HT22 cells, as well as RSL3-induced ferroptosis in HSC-LX2, and MIA PaCa-2 cells. |
| PC-28363 |
THTZO4a
Ferroptosis inhibitor
|
THTZO4a is a potent nonclassical radical-trapping antioxidant and ferroptosis inhibitor with EC50 of 92 nM, effectively suppresses erastin-induced ferroptosis in HT22 cells, as well as RSL3-induced ferroptosis in HSC-LX2, and MIA PaCa-2 cells. |
| PC-28285 |
ACXT-3102
Ferroptosis inducer, xCT inhibitor
|
ACXT-3102 (SW V-49) is a cancer-specific drug conjugate and ferroptosis inducer consisting of a pro-apoptotic sigma-2 ligand as a delivery moiety (SV119), linked to an inhibitor of the cystine antiporter xCT (des-methyl Erastin, dm-Erastin), exhibits potent, targeted therapeutic for pancreatic cancer cells. |
| PC-27626 |
4-Hydroxynonenal
ALDH2 substrate, Ferroptosis inducer
|
4-Hydroxynonenal (4-HNE) is a lipoperoxidation-derived aldehyde and ALDH2 substrate that promotes oxidative stress, induces ferroptosis, and aggravates myocardial injury, directly evokes myocyte ferroptosis by interacting with GPX4 and deubiquitinase OTUD5 at cysteine residues, leading to increased ubiquitination and degradation of GPX4. |
| PC-26804 |
FXT-003
Ferroptosis inhibitor
|
FXT-003 (FXT003) is a highly potent, effective, orally bioavailable next-generation ferroptosis inhibitor with IC50 of 11.7 nM in HT-1060 cells. |
| PC-26803 |
FXT-002
Ferroptosis inhibitor
|
FXT-002 (FXT002) is a highly potent, effective, orally bioavailable next-generation ferroptosis inhibitor with IC50 of 6.91 nM in HT-1060 cells, shows dual radical and iron-trapping activity. |
| PC-26734 |
Sulfasalazine
SLC7A11/xCT inhibitor, Ferroptosis inducer
|
Sulfasalazine (NSC 667219) is a disease-modifying antirheumatic drug used to treat arthritis and ankylosing spondylitis, is a SLC7A11/xc(-) cystine/glutamate antiporter (xCT) inhibitor, has anti-leukemic activity against primary AML samples, is also a ferroptosis inducer. |
